Restraints
In 2012, Pfizer Inc. and Johnson & Johnson, announced to discontinue the development of Alzheimer drug which was in intravenous (IV) form – bapineuzumab as drug failed to help patient with memory robbing condition in a second high profile clinical trial. Such failures, deter the expected growth of a market.
Increasing prevalence and incidence of Alzheimer disease is expected to favor the growth of Anti Beta Alzheimer Therapies Market
Increasing aging population along with its associated complications, such as dementia is the major driving factor for the growth of Anti-β-Alzheimer therapies market. For instance, according to Centers of Disease Control and Prevention (CDC), 2013, five million Americans were suffering from AD and the number is expected to rise up to 14 million by 2050. Moreover, according to World Health Organization (WHO), 2017, approximately 47 million people have dementia and nearly 10 million new cases are reported annually.
According to Australian Bureau of Statistics (ABS) in 2013, dementia was the second leading cause of death in Australia. According to Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach around 400,000 by 2020, and around 900,000 by 2050. The National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to priorities and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment and care for dementia patients. Increasing prevalence and incidence of Alzheimer disease and its complication worldwide and rise in demand for therapy is expected to favor the growth of Anti-β-Alzheimer therapies market in near future.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients